Bio-Techne Cash Flow Statement
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Techne free cash flow
In fiscal 2026, Bio-Techne generated $292.1 million of operating cash flow and spent $28.9 million on capital expenditures. That left free cash flow of $263.2 million, a free-cash-flow margin of 21.7% of revenue. Free cash flow was up 2.6% from the prior year's $256.6 million.
Bio-Techne returned $91.6 million to shareholders: $49.9 million in dividends and $41.7 million in share repurchases, equal to 35% of free cash flow. Free cash flow covered dividend payments 5.3 times.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Techne cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-06-30 | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 181.86M | 73.40M | 168.10M | 285.44M | 263.10M | 139.59M | 229.30M | 96.07M | 126.15M | 76.09M |
| Net Income growth (YoY) | +147.77% | -56.34% | -41.11% | +8.49% | +88.49% | -39.12% | +138.67% | -23.84% | +65.80% | -27.17% |
| Depreciation & Amortization | 97.36M | 109.90M | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M |
| Stock-Based Compensation | 41.37M | 40.83M | 38.04M | 39.23M | 42.18M | 48.98M | 32.37M | 32.28M | 28.24M | 14.63M |
| Change in Working Capital | -15.85M | 2.03M | -8.98M | -58.94M | -76.86M | -3.60M | 2.04M | -22.55M | -11.00M | -14.72M |
| Operating Cash Flow | 292.07M | 287.56M | 298.98M | 254.39M | 325.27M | 352.16M | 205.22M | 181.62M | 170.37M | 143.72M |
| Capital Expenditures | -28.85M | -31.01M | -62.88M | -38.24M | -44.91M | -44.30M | -51.74M | -25.41M | -20.93M | -15.18M |
| Investing Cash Flow | -18.19M | -35.18M | -203.03M | -265.65M | -96.85M | -243.52M | 27.09M | -336.80M | -38.71M | -305.95M |
| Dividends Paid | -49.92M | -50.39M | -50.42M | -50.28M | -50.19M | -49.62M | -48.90M | -48.36M | -47.97M | -47.33M |
| Share Repurchases | -41.67M | -275.73M | -80.04M | -19.56M | -160.95M | -43.18M | -50.11M | -15.40M | 0 | — |
| Financing Cash Flow | -169.11M | -253.91M | -122.40M | 22.62M | -242.85M | -62.55M | -183.80M | 134.38M | -99.19M | 189.11M |
| Net Change in Cash | 102.53M | 10.39M | -28.78M | 8.00M | -26.52M | 52.47M | 45.74M | -21.10M | 30.38M | 27.38M |
| Free Cash Flow | 263.22M | 256.55M | 236.10M | 216.15M | 280.36M | 307.86M | 153.47M | 156.21M | 149.43M | 128.54M |
This table shows 10 annual periods of Bio-Techne's cash flow statement, from FY 2026 back to FY 2017, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TECH's reporting calendar. What is a cash flow statement?